1. Cellestia Biotech AG - Company Presentation
First-in-class Pan-NOTCH inhibitor for anti-cancer Therapy
March 2016

2. Cellestia Biotech AG (S.A.): Company History & Profile
Spin-off from Swiss Institute for Experimental Cancer Research at EPFL, Lausanne, Switzerland
Incorporation May 2014 by Prof. F. Radtke and R. Lehal
Co-founding Development Team joined September adding management & pharma development expertise
Headquarter & Development Office at Technology Park, Basel; Research continues at EPFL, Lausanne
Worldwide exclusive License Agreement on IP from EPFL TTO in June 2014, US Patent granted 3/2016
SEED Financing A successfully closed, SEED B ongoing, Series A target in 4Q2016 / 1Q2017
Development activities ongoing (e.g. manufacture, IND/CTA enabling studies)
Target to reach clinical development Ph I by 1Q2017
Cellestia Biotech Offices:
Innovation Square
EPFL Building C
CH-1015 Lausanne, Switzerland
Hochbergerstrasse 60C
CH-4057 Basel, Switzerland

3. Cellestia Biotech S.A. Management: Decades of Experience in R&D
Dr. Michael Bauer
CEO
Prof. Freddy Radtke
Chairman BoD
Dr. Rajwinder Lehal
CSO
Dr. Dirk Weber
CMO
Dr. Richard Peck
Regulatory Affairs
Professional and Experienced Management Team
Scientific Excellence at EPFL Research (Prof. Freddy Radtke & Rajwinder Lehal, PhD)
Drug Development Expertise from Biotech and Big Pharma (Michael Bauer, PhD)
Medical Oncology Development and Medical Affairs Experience (Dirk Weber, MD, PhD)
Global Regulatory Affairs Experience (Richard Peck, PhD)
Track record of professional success and achievements
Over 100 scientific papers in leading journals, invited speaker at top conferences
Successful leadership bringing products into clinic, achieving clinical proof of concept, gaining product registrations and successful commercial launch

4. Advisory Boards: Business, Institutional, Scientific & Medical
Business Advisors:
ROGER MEIER
Clarena AG, Corporate Development and Private Equity Facilitation
CHRISTOPH RENTSCH
CFO at Santhera AG, Strategic Finance and designated member of the BoD
RALF ROSENOW
Blum & Grob, Attorneys at Law Ltd, General Legal Counsel
URS BREITENSTEIN
Hoffmann & Co, Financial Services (payroll, tax and accounting)
ANDREAS SCHÖLLHORN
LS Partners, Basel; Intellectual property
Institutional Support:
EPFL, Lausanne
Research & Development
I-NET INNOVATION NETWORKS, Basel
INNOVATION PARK,
EPFL Lausanne
INNOVAUD
Canton of Vaud, Lausanne
SERVICE DE LA PROMOTION ECONOMIQUE &COMMERCE (SPECo), VAUD
KOMMISSION FUR TECHNOLOGIE UND INNOVATION (KTI), Bern)
Financing R&D
Scientific Advisory Board:
DR. DORIANO FABBRO
Preclinical Pharmacology, Basel
DR. MARC LANG
Medicinal Chemistry, Basel
DR. ROBERT ETTLIN
Toxicology, Basel
PROF. CHANTAL CSAJKA
PK/ADME, Lausanne
DR. PAOLO NUCIFORO
Head Molecular Oncology Group, Vall d`Hebron, Barcelona
Medical Advisory Board:
PROF. RICHARD HERRMANN
Medical Oncology, Basel
PROF. JAVIER CORTES
Medical Oncology; Vall d`Hebron, Barcelona
PROF. JOSEP TABERNERO
Head Med Oncology Department & Director Vall d’Hebron Institute of Oncology (VHIO)
PROF. FRANCESC BOSCH ALBAREDA
Head Hematology Department, Vall d`Hebron, Barcelona
PROF. MARTIN DREYLING
Medical Hemato-Oncology, LMU Munich
Cellestia has been very successful in attracting internationally recognized experts in business, preclinical and clinical research and development

5. What is NOTCH ?
Cell-to-Cell communication mechanism of physically directly adjacent cells
Cancer
Growth, Metastasis, Invasion, Blood vessel formation, Cancer Stem Cells
constitutive activation
Signal Sending Cell: „Ligand“
 5 NOTCH activating ligands
DLL1, DLL3, DLL4
JAG1, JAG2
Signal Receiving Cell: „Receptor“  4 NOTCH receptors
NOTCH
Gamma Secretase
CB-103
on / off
Signal Translation: „NICD“ triggers transcription in cell nucleus
Selective Effect: „downstream“ proteins produced due to NOTCH activation:
Driving cancer if out of control
Adopted from : Andersson & Lendahl
Nature Reviews Drug Discovery, MAY 2014; VOLUME 13

6. New Mode of Action: Central control of NOTCH driven cancer
Why is CB-103 unique?
New Mode of Action: Central control of NOTCH driven cancer
constitutive activation
Adopted from : Andersson & Lendahl
Nature Reviews Drug Discovery, MAY 2014; VOLUME 13
Competitor products:
1. Inhibitors of activating ligands:
2. Inhibitors of NOTCH receptors:
3. Gamma-secretase inhibitors:
Central Control: blocking NOTCH regardless of mechanistic cause
Proliferation
Resistance to Cell Death
Angiogenesis
 Incomplete control
Invasion
Metastasis
STOP
Cancer Stem Cells

7. Clinical Relevance & Validation:
Patients´ life expectance depends on NOTCH status
Breast Cancer (BC):
High level co-expression of JAG1 and NOTCH1
Associated with poor survival (median OS):
High NOTCH1: 40 mths
Low NOTCH1: 83 mths
Reedjik et al.
Cancer Research 2005
Low NOTCH1
High NOTCH1
Significantly shorter survival for patients with upregulated NOTCH activation
NOTCH is a clinically validated target – anti NOTCH drugs show clinical efficacy

8. Is CB-103 active against cancer?
TNBC: Triple Negative Breast Cancer, patient derived,
GSI resistant (constitutive activation, no competitor)
Clear Disease Control
Confirmed down-regulation of pathway biomarkers
Well tolerated daily treatments

9. Is CB-103 active against cancer?
T-ALL: Acute Lymphocytic T-Cell Leukaemia, patient derived blood sample, resistant to chemo & experimental therapies
Toxic conc. of
CB-103
Selective killing of leukemic cells in NOTCH positive disease
Synergy in chemo-combination
Survival benefit (mouse model)
Well tolerated daily treatments

10. CB-103: Development Plan, Financing & Valuation Inflection Points
CHF 0.5 m Seed A financing completed
non-GMP manufacture established, ready for GMP manufacture, formulation development started
Toxicology studies have been initiated
CHF m Seed B financing round open: GMP manufacture, GLP tox and IND filing for Phase I

11. TOP NOTCH Investment Rationale
People: Top Team with professional track record
Patent: Exclusive License on IP; US granted
Product: CB-103 is first and potentially best-in class
Control NOTCH independent of the cause, access largest possible patient pool
CB-103 has a good safety profile in toxicity profiling and animal studies thus far
Very attractive target pursued by big pharma, attractive deal market for profitable exit
Clinically validated and relevant target with first proof of concept observed
Expect excellent margins : Small molecule, easy and cost – effective to produce
Medical Need & Market Potential:
Over 250´000 newly diagnosed patients with NOTCH activation in various indications diagnosed annually, with currently no targeted treatment
Market potential > 10 billion
Cellestia sales projections for CB-103 reaching CHF 1bn peak sales
Increased chance of success by combining with companion diagnostic

12. For more information contact:
Michael Bauer, CEO
Cellestia Biotech AG
Hochbergerstrasse 60C
4057 Basel, Switzerland
Phone:
Mobile:
Cellestia Biotech Research:
Innovation Square, EPFL Building C
1015 Lausanne, Switzerland
Phone: and 0774